All News
Risk of RA-ILD is 15% (or 1 in 6) according to Mayo clinic (Olmstead county) data. @jeffsparks https://t.co/KynitLCsK7
Dr. John Cush RheumNow ( View Tweet)
#RA with ILD portends poor outcomes, especially if seropositive. Visiting professor Dr. Jeff sparks @jeffsparks @UTSW_Rheum https://t.co/fbVyDMUm6L
Dr. John Cush RheumNow ( View Tweet)
RA Patients on Biologics and tsDMARDs are still High Risk
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
Read Article
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis
A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.
Read Article
Dr. Megan Clowse discusses the differences in pregnancy planning for men and women with rheumatic disease, with particular focus on medication use. Watch now.
https://t.co/Ine8CdbZR4 https://t.co/7UnanlnQcC
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
Read Article
Dutch Biologic Monitor surveys of RA, PsA, axSpA pts on etanercept or adalimumab, looked at adverse drug reactions. Among 748 consecutive pts on biologics, women had more ADRs (55%) than men (38%). nature ofreported ADRs differed betw sexes (p = 0.02). https://t.co/fGRgX4IJLR https://t.co/FJE7BrKPfQ
Links:
Dr. John Cush RheumNow ( View Tweet)
962 #RA pts from Leiden early arthritis clinic shows that in 2005 was a significant delay (~5wks) in referral of females vs male pts. The longer referral delays in female pts has since been eliminated. By 2020 the referral delay is same 4.7 vs 5.4 wks. https://t.co/JphiWWk85j https://t.co/bEHKLot4hu
Links:
Dr. John Cush RheumNow ( View Tweet)
The Origin Story: Women in Rheumatology--The XX Factor
When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field.
https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL
Links:
Dr. John Cush RheumNow ( View Tweet)
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor.
Sign up to attend our Tuesday Night Rheumatology series.
@uptoTate @KDAO2011
https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN
Links:
Dr. John Cush RheumNow ( View Tweet)
Among 182 adult #RA pts - half (50%) had Depression and 25% had anxiety. Patients with depression or anxiety had higher HAQ and DAS28 scores. Depression was more prevalent in females, housewives, & low education. Anxiety more in blue-collar workers https://t.co/C9Foulu29l https://t.co/tcCaV85kU0
Links:
Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology.
Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations.
https://t.co/OlP0pupkMV https://t.co/pZQMASafcG
Links:
Dr. John Cush RheumNow ( View Tweet)
Variability in rheumatologist steroid prescribing - using data on ~500k RA pts and 6,875 rheumatologists. Those LESS likely to prescribe alot of steroids were: women, solo practitioners, in practice ≥10 years, seeing greater#s of RA pts/year https://t.co/ELk0avorOe
Links:
Dr. John Cush RheumNow ( View Tweet)
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/dsbjPhuYzf https://t.co/1Zmyqjuaxj
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E
Links:
Dr. John Cush RheumNow ( View Tweet)
Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM
Links:
Dr. John Cush RheumNow ( View Tweet)
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/T7CRLzhOMD https://t.co/nYPEw72zOJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/XKjuxLWAKH https://t.co/M7ri9AL2wH
Links:
Dr. John Cush RheumNow ( View Tweet)
What to do about pre-clinical RA?
Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056
Links:
Dr. John Cush RheumNow ( View Tweet)